| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?
|
Soverini, Simona
|
|
2019
|
6 |
5 |
p. e236-e237
|
article
|
| 2 |
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
|
Bashir, Qaiser
|
|
2019
|
6 |
5 |
p. e266-e275
|
article
|
| 3 |
Correction to Lancet Haematol 2019; 6: e183–93
|
|
|
2019
|
6 |
5 |
p. e238
|
article
|
| 4 |
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
|
Kizilors, Aytug
|
|
2019
|
6 |
5 |
p. e276-e284
|
article
|
| 5 |
Forging a path for chronic myelomonocytic leukaemia
|
The Lancet Haematology,
|
|
2019
|
6 |
5 |
p. e229
|
article
|
| 6 |
Gene therapy for Wiskott-Aldrich syndrome: here to stay
|
Candotti, Fabio
|
|
2019
|
6 |
5 |
p. e230-e231
|
article
|
| 7 |
Improving the conditioning regimen in multiple myeloma
|
Mateos, María-Victoria
|
|
2019
|
6 |
5 |
p. e234-e235
|
article
|
| 8 |
Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
|
Ferrua, Francesca
|
|
2019
|
6 |
5 |
p. e239-e253
|
article
|
| 9 |
Monoclonal antibody-drug conjugates in B-cell lymphomas
|
Chiappella, Annalisa
|
|
2019
|
6 |
5 |
p. e232-e233
|
article
|
| 10 |
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
|
Morschhauser, Franck
|
|
2019
|
6 |
5 |
p. e254-e265
|
article
|
Journal description